-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Protocols & Best Us
2026-06-05
The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides sensitive, specific detection of rabbit IgG in fluorescence-based immunoassays, supporting applications such as immunofluorescence, IHC, and ICC. It is not intended for diagnostic, clinical, or non-rabbit primary antibody workflows. Adhering to recommended protocols and storage conditions is essential for reproducible results.
-
CHI3L1-IN-5 (Compound Z17): Selective NF-κB Pathway Inhibito
2026-06-05
CHI3L1-IN-5 (Compound Z17) is a potent, selective inhibitor of CHI3L1 with nanomolar binding affinity and robust CNS penetration. It blocks CHI3L1-mediated NF-κB signaling and restores astrocyte function impaired by amyloid-β. These properties position it as a promising tool and candidate for Alzheimer’s disease research.
-
Capsaicin (E)-Capsaicin: Bridging TRPV1, Epigenetics, and Se
2026-06-04
Explore how Capsaicin (E)-Capsaicin advances sensory neuron research by uniquely connecting TRPV1 ion channel activation with epigenetic modulation. Discover new mechanistic insights and protocol guidance distinct from standard cell assay approaches.
-
Kanamycin Sulfate: Water-Soluble Antibiotic for Cell Selecti
2026-06-04
Kanamycin Sulfate offers precision and reliability for antibiotic resistance research and advanced microbiology workflows. With high purity and robust water solubility, it is a benchmark for cell culture selection and bacterial protein synthesis inhibition.
-
Partial BACE1 Inhibition Preserves Synaptic Function in AD M
2026-06-03
Satir et al. (2020) demonstrated that moderate inhibition of BACE1—reducing amyloid-beta production by up to 50%—does not impair synaptic transmission in cultured neurons. This finding clarifies a key safety margin for BACE1 inhibitors in Alzheimer's disease research and supports targeted, dose-optimized approaches to modulate amyloidogenic pathways.
-
Applied Workflows with Amyloid β-Peptide (1-42): Assay Preci
2026-06-03
Leverage Amyloid β-Peptide (1-42) (Aβ42) from APExBIO for robust Alzheimer's disease models, advanced neurotoxicity assays, and sensitive detection of amyloid pathology. This guide delivers protocol optimization, troubleshooting, and practical insights to maximize reproducibility and analytic power in Aβ42-driven research.
-
Potassium Iodide in Advanced Thyroid & Immunotherapy Researc
2026-06-02
Potassium Iodide (KI) is indispensable for thyroid protection and experimental modulation of hormone synthesis, enabling robust, reproducible workflows in both classic and next-generation research. This article delivers protocol enhancements, troubleshooting insights, and crosslinks the latest advances in nanotechnology-driven immunotherapy to actionable KI use-cases.
-
Protease Inhibitor Cocktail (EDTA-Free): Reliable Protein St
2026-06-02
This article addresses real laboratory challenges in cell viability and protein extraction workflows, demonstrating how the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K4002) from APExBIO acts as a robust protein stability enhancer. Drawing on peer-reviewed research and validated protocols, it guides scientists toward reproducible, high-yield results in OXPHOS and cancer metabolism assays.
-
Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis
2026-06-01
This study establishes a novel four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma (HCC) and experimentally validates atorvastatin as a potential ferroptosis inducer that inhibits HCC cell growth and migration. The findings provide a new molecular framework for prognosis prediction and suggest new directions for therapeutic intervention in HCC.
-
NLRP10's Role in Keratinocyte Survival and Skin Barrier Func
2026-06-01
This study uncovers NLRP10 as a critical regulator of keratinocyte survival and p63-dependent differentiation, directly linking genetic risk at the NLRP10 locus to impaired epidermal barrier function in atopic dermatitis. The findings provide mechanistic insight into how NLRP10 downregulation contributes to disease pathogenesis and highlight its therapeutic potential.
-
Atorvastatin (SKU C6405): Reliable Solutions for Cell-Based
2026-05-31
This evidence-based article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how Atorvastatin (SKU C6405) provides reproducible and data-backed solutions. Practical scenarios guide biomedical researchers and technicians through protocol optimization, data interpretation, and vendor selection—anchored by validated protocols and mechanistic insights.
-
Erastin (B1524): Reliable Ferroptosis Inducer for Cancer Bio
2026-05-30
Erastin (SKU B1524) is a rigorously characterized ferroptosis inducer, widely adopted for reproducible cell death and oxidative stress assays in cancer biology research. This article details scenario-driven solutions for experimental design, protocol optimization, and vendor selection—guiding researchers to leverage Erastin’s validated performance and compatibility in RAS/BRAF-driven tumor models.
-
rTMS Promotes Amyloid Clearance via GABAergic Modulation in
2026-05-29
This study reveals that repetitive transcranial magnetic stimulation (rTMS) enhances cognitive recovery in Alzheimer's disease by activating GABAergic neurons and upregulating the Cx3cl1-Cx3cr1 axis, thereby facilitating microglial phagocytosis and reducing amyloid plaque burden. These insights highlight a molecular pathway for non-invasive AD intervention and suggest new therapeutic research directions.
-
(R,S)-Anatabine in Alzheimer’s Models: Protocols & Pitfalls
2026-05-29
(R,S)-Anatabine delivers targeted, dual-mechanism inhibition of amyloidogenesis and neuroinflammation, making it a standout tool for translational Alzheimer’s disease research. This article details experimental workflows, troubleshooting, and actionable insights for optimizing its use in both in vitro and in vivo AD models.
-
RITA (NSC 652287): Strategic Leverage in Translational Oncol
2026-05-28
RITA (NSC 652287) exemplifies a new era in translational cancer research, bridging deep mechanistic understanding of the p53 pathway with actionable strategies for apoptosis assays and in vivo tumor models. This article explores RITA’s dual DNA cross-linking and MDM2-p53 disruption, offers workflow guidance, and contextualizes its value in the evolving landscape of cancer biology—delivering a roadmap for researchers seeking reliable, high-impact tools from APExBIO.